基立福 GRFS
$8.43 −$0.03 (-0.35%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $8.43 0.00%
开盘$8.30
昨收$8.46
当日区间$8.26 – $8.55
成交量610.3K
市值$5.74B
市盈率（TTM）10.5
股息率1.25%
GRFS 相关新闻
匹配 Grifols 或代码 GRFS 的头条新闻，按最新排序。
- FOXO Unit to Acquire Four U.S. Blood Collection Centers From Grifols Subsidiary
- FOXO TECHNOLOGIES INC.'S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
- Grifols S.A. Q2 2026 Earnings Preview
- Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous Immunoglobulin
- GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS To Go Ex-Dividend On June 30th, 2026 With 0.09363 USD Dividend Per Share
- Grifols, S.A. Sponsored ADR (Each Representing 1/2 Ordinary Shares of EUR 0.50) (GIKLY.US) will release its financial report on November 2.
- J.P. Morgan Maintains Grifols(GRFS.US) With Hold Rating, Cuts Target Price to $9 负面
- J.P. Morgan Maintains Grifols(GRFS.US) With Hold Rating, Cuts Target Price to $10.3 负面
- J.P. Morgan Initiates Grifols(GRFS.US) With Hold Rating, Announces Target Price $10
- Berenberg Bank Maintains Grifols(GRFS.US) With Buy Rating, Cuts Target Price to $16.71 负面
- GRIFOLS SA SPON ADR EA REPR 1/2 ORD SHS EUR0.50 | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
- Shanghai RAAS Blood Products: Special Audit Opinions on Grifols Diagnostic Solutions, Inc.'s Statement of Achievement of the 2019-2023 Performance Commitments
- Shanghai RAAS Blood Products: Explanation of Grifols Diagnostic Solutions, Inc.'s achievement of its 2019-2023 performance commitments
- GRIFOLS SA SPON ADR EA REPR 1/2 ORD SHS EUR0.50 | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
- GRIFOLS SA NON-CUM PRF SHS EUR0.05 (B) POST CONS | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
暂无评论——快来第一个聊聊 GRFS。
登录后参与讨论。